Skip to main content
    N

    Nyxoah (NYXH)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $0.89
    -0.01 (-0.64%)

    Market Cap: $91.61M

    Last updated: Nov 17, 2026 at 10:51 AM ET

    Nyxoah (NYXH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in EUR.

    Nyxoah reported revenue of EUR 10.02M for the fiscal year ended Dec 31, 2025, up 121.6% from the year before. That year, net income was EUR -90.08M with a net margin of -899.1%, operating cash flow was EUR -67.50M and free cash flow was EUR -68.30M. The quarter ended Sep 30, 2026 had revenue of EUR 9.17M and net income of EUR -17.83M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from EUR 69.00K, a compound annual rate of 170.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 202510.02M+121.6%63.1%-827.8%-899.1%
    Dec 20244.52M+4.0%65.7%-1300.8%-1310.2%
    Dec 20234.35M+41.0%61.9%-1037.3%-993.8%
    Dec 20223.08M+262.0%62.7%-1053.8%-1012.5%
    Dec 2021852.00K+1134.8%64.4%-3080.0%-3241.7%
    Dec 202069.00KN/A56.5%-16266.7%-17746.4%
    Dec 20190N/AN/AN/AN/A
    Dec 20180N/AN/AN/AN/A
    Dec 20170N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue10.02M4.52M4.35M3.08M852.00K69.00K000
    Cost of revenue3.69M1.55M1.66M1.15M303.00K30.00K486.04K95.08K89.25K
    Gross profit6.33M2.97M2.69M1.93M549.00K39.00K-486.04K-95.08K-89.25K
    Research and development42.82M34.33M27.66M15.86M5.95M2.91M1.64M1.37M1.53M
    Operating income-82.94M-58.81M-45.10M-32.50M-26.24M-11.22M-8.52M-8.45M-10.14M
    Net income-90.08M-59.24M-43.21M-31.23M-27.62M-12.24M-8.45M-9.08M-10.37M
    EBITDA-82.90M-51.81M-42.08M-27.89M-22.59M-10.60M-8.28MN/A-8.65M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue9.17M7.67M7.36M5.64M1.97M1.34M1.06M1.26M1.27M771.00K1.22M1.82M
    Gross profit5.79M4.58M2.22M3.63M1.19M850.00K658.00K928.00K784.00K490.00K766.00K1.10M
    Operating income-21.87M-20.59M-23.73M-18.26M-24.20M-19.85M-20.64M-18.31M-14.98M-13.31M-12.21M-10.84M
    Net income-17.83M-32.96M-18.42M-23.51M-23.58M-20.61M-22.38M-17.15M-17.06M-13.12M-11.91M-10.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of EUR 39.83M exceeded cash and equivalents by 9.84M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets118.43M158.41M124.16M146.07M170.83M139.58M17.06M17.98M11.14M
    Current assets61.19M98.08M68.35M100.26M140.06M115.15M8.95M17.54M10.68M
    Cash and equivalents29.99M34.19M21.61M17.89M135.51M112.93M6.57M16.80M10.11M
    Total liabilities69.34M45.15M26.14M25.75M22.21M20.67M14.41M7.53M6.62M
    Short-term debt23.76M1.37M1.22M1.11M1.14M1.33M805.95K289.00K395.00K
    Long-term debt16.07M18.73M8.37M8.19M7.80M7.61M7.15M5.53M4.87M
    Shareholder equity49.11M113.25M98.02M120.32M148.62M118.92M2.65M10.45M4.53M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets148.72M168.47M97.97M118.47M93.60M116.47M135.90M158.41M142.76M148.23M113.02M124.16M
    Total liabilities80.77M85.36M61.96M69.34M42.65M43.07M43.06M45.15M38.06M28.09M25.82M26.05M
    Cash and equivalents15.43M64.11M12.98M30.00M10.87M22.73M22.39M34.19M28.68M27.72M22.08M21.61M
    Shareholder equity67.96M83.11M36.01M49.13M50.95M73.40M92.84M113.25M104.71M120.21M87.20M98.11M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-67.50M-49.23M-44.78M-28.76M-25.34M-6.86M-5.93M-8.14M-8.29M
    Capital expenditures804.70K6.07M10.96M16.35M11.82M10.68M5.79M77.00K91.00K
    Free cash flow-68.30M-55.30M-55.74M-45.10M-37.15M-17.54M-11.72M-8.22M-8.38M
    Investing cash flow26.17M-16.32M32.01M-89.95M-11.82M-10.69M-5.79M-75.00K-91.00K
    Financing cash flow38.79M77.44M16.86M-983.00K76.47M104.03M700.00K15.00M1.11M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-21.01M-16.57M-21.63M-13.11M-20.48M-16.73M-18.52M-12.20M-13.44M-11.31M-12.28M-11.68M
    Capital expenditures441.00K1.28M727.75K20.99K23.00K551.00K210.00K1.55M776.00K1.33M2.41M1.74M
    Free cash flow-21.45M-17.86M-22.36M-13.13M-20.51M-17.28M-18.73M-13.75M-14.21M-12.64M-14.69M-13.41M
    Last 12 quarters

    Frequently Asked Questions About NYXH

    What is Nyxoah's annual revenue?

    Nyxoah reported revenue of EUR 10.02M for the fiscal year ended Dec 31, 2025.

    How fast is Nyxoah's revenue growing?

    Revenue was up 121.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 48.1%.

    Is Nyxoah profitable?

    No. Nyxoah reported net income of EUR -90.08M for the fiscal year ended Dec 31, 2025, with a net margin of -899.1%.

    How much free cash flow does NYXH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -67.50M minus capital expenditures of EUR 804.70K produced free cash flow of EUR -68.30M.

    How much debt does Nyxoah have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 16.07M, short-term debt of EUR 23.76M and cash and equivalents of EUR 29.99M.